MICs of eight j-lactams (piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone) were determined by agar dilution against 64 penicillinsusceptible, 70 intermediately penicillin-resistant, and 66 fully penicillin-resistant pneumococci. The MICs of piperacillin with and without tazobactam for 90Y% of the susceptible, intermediately resistant, and resistant strains tested (MIC90s) were .0.064, 2.0, and 4.0 ,ig/ml, respectively. By comparison, those of ampicillin with and without sulbactam were 0.125, 2.0, and 4.0 ,ug/ml and those of ceftriaxone were s0.064, 1.0, and 2.0 ,ug/ml, respectively. Strains were less susceptible to ticarcillin with and without clavulanate (MIC90s, 2.0, 64.0, and 128.0 jig/ml) and ceftazidime (MIC90s, 1.0, 8.0, and 32.0 I,g/ml).
Streptococcus pneumoniae continues to be a significant cause of morbidity and mortality in humans and is the leading cause of bacterial pneumonia, as well as an important cause of otitis media and meningitis. The past 2 decades, and in particular the past 5 years, have witnessed a dramatic increase in the incidence of pneumococcal strains which are resistant to penicillin G and other antimicrobial agents (1, 2, (5) (6) (7) 9) . In the United States, recent surveys show a countrywide prevalence of 4 to 5% (1) . McDougal and coworkers have recently documented the dissemination in the United States of a multiresistant type 23F clone which is related to multiresistant isolates from Spain and South Africa (12) , emphasizing the tendency of these strains to spread from country to country and even from continent to continent. The problem has recently been exacerbated by the appearance of pneumococci with high-level resistance to cefotaxime and ceftriaxone (3, 4, 14) . Although nonmeningitic infections caused by pneumococci with intermediate penicillin resistance (I strains) may be treated, under certain circumstances, with large doses of penicillin and other ,-lactams, treatment may not always be successful (2, 5, 7, (9) (10) (11) 16) . By contrast, clinical failure of penicillin in the treatment of meningitis caused by I strains approaches 80% and very few cases of meningitis caused by strains fully resistant to penicillin (R strains) have responded to penicillin therapy (2, 5, 7, (9) (10) (11) 16) .
There is an urgent need for antimicrobial agents which can be used for parenteral therapy of systemic infections caused by penicillin-resistant pneumococci. Ward and Moellering, in 1981 , described low MICs of piperacillin for penicillin-susceptible strains (S strains), I strains, and R strains of pneumococci (17) . Subsequently, Tweardy and coworkers, in 1983 (16), described similarly improved activity of piperacillin compared with ticarcillin and ceftazidime against the same groups of organisms. The aim of the current study was to confirm and extend these findings by examining the activity of eight ,B-lac- Results of susceptibility testing are presented in Table 1 . As ANTIMICROB. AGENTS CHEMOTHER. Our findings with a larger group of pneumococci, with I and R strains isolated from several different countries, are similar to these reports. High MICs of ceftazidime, in contrast to lower MICs of ceftriaxone against I and R pneumococcal strains, have been described before (10, 11) . Because the mechanism of ,-lactam resistance in pneumococci is mediated by changes in penicillin-binding proteins (8) , the activity of ,-lactam-3-lactamase inhibitor combinations against I and R pneumococci is due solely to the ,-lactam component. Sorgel and Kinzig (15) have reported human pharmacokinetic data for piperacillin with and without tazobactam. After a 5-min intravenous infusion of piperacillin alone, the maximum concentration of the drug in serum was 380.0 (4-g dose) or 178 (2-g dose) ,ug/ml. When 4 g of piperacillin was given as a 30-min infusion, the mean maximum level in plasma was 284 ,ug/ml, about 75% of There are currently no breakpoints for pneumococci recommended by the National Committee for Clinical Laboratory Standards for the ,-lactams tested in this study other than ceftriaxone (13) . In view of the rapid worldwide spread of I and R strains, this deficiency requires urgent rectification. MICs for piperacillin with and without tazobactam against R pneumococci are clearly lower than the levels achievable in serum and tissue. This is particularly true for I strains, which account for >90% of the penicillin-resistant pneumococci isolated in the United States (1). Additionally, in view of the above-mentioned pharmacokinetic data, serum piperacillin levels sufficient to inhibit I and R organisms may be achievable in humans. Clinical studies are necessary to ascertain whether piperacillin with and without tazobactam may represent an alternative to cefotaxime or ceftriaxone for therapy of systemic nonmeningeal infections caused by I and R pneumococci.
